Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

[1]  S. Buscemi,et al.  Two-year Effect of Semaglutide 2.4 mg Versus Placebo in Adults With Overweight or Obesity: STEP 5 , 2022, Canadian Journal of Diabetes.

[2]  M. Lipš,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, Anesteziologie a intenzivní medicína.

[3]  P. Norwood,et al.  Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. , 2022, JAMA.

[4]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[5]  J. Minx,et al.  Decision makers need constantly updated evidence synthesis , 2021, Nature.

[6]  G. Filippatos,et al.  Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis , 2021, European heart journal.

[7]  J. Rosenstock,et al.  Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial , 2021, The Lancet.

[8]  K. Khunti,et al.  COVID-19 and metabolic disease: mechanisms and clinical management , 2021, The Lancet Diabetes & Endocrinology.

[9]  G. Filippatos,et al.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. , 2021, The New England journal of medicine.

[10]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[11]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[12]  B. Ludvik,et al.  Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial , 2021, The Lancet.

[13]  S. Verma,et al.  Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet Diabetes & Endocrinology.

[14]  J. Rosenstock,et al.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. , 2021, The New England journal of medicine.

[15]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[16]  J. Rosenstock,et al.  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial , 2021, The Lancet.

[17]  L. Reitzle,et al.  Diabetes mellitus and comorbidities – A cross-sectional study with control group based on nationwide ambulatory claims data , 2021, Journal of health monitoring.

[18]  H. Rodbard,et al.  Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. , 2021, Diabetes research and clinical practice.

[19]  P. Ponikowski,et al.  Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.

[20]  C. Wanner,et al.  Report from the CVOT Summit 2020: new cardiovascular and renal outcomes , 2021, Cardiovascular Diabetology.

[21]  F. Greenway,et al.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. , 2021, JAMA.

[22]  T. Wadden,et al.  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial , 2021, The Lancet.

[23]  T. Wadden,et al.  Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. , 2021, JAMA.

[24]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[25]  David W. Johnson,et al.  Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials , 2021, BMJ.

[26]  6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. , 2021, Diabetes care.

[27]  S. Bain,et al.  The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials , 2020, Diabetes Therapy.

[28]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[29]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[30]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[31]  G. Hu,et al.  Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study , 2020, Diabetes Care.

[32]  Rodolfo J. Galindo,et al.  Continuous Glucose Monitoring: the achievement of 100 years of innovation in diabetes technology. , 2020, Diabetes research and clinical practice.

[33]  Deborah A. Greenwood,et al.  The Role of Blood Glucose Monitoring in Diabetes Management , 2020, ADA Clinical Compendia.

[34]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[35]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[36]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[37]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[38]  J. Ayres,et al.  A metabolic handbook for the COVID-19 pandemic , 2020, Nature metabolism.

[39]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[40]  X. Cos,et al.  Report from the 5th cardiovascular outcome trial (CVOT) summit , 2020, Cardiovascular Diabetology.

[41]  H. Rodbard,et al.  Proceedings of the Guideline Workshop 2019 - Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases and Kidney Diseases. , 2020, Diabetes research and clinical practice.

[42]  I. D. de Boer,et al.  Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease , 2020, BMJ Open Diabetes Research & Care.

[43]  B. Zinman,et al.  Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.

[44]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[45]  G. Filippatos,et al.  Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.

[46]  Tiffany D. Rau,et al.  Current perspectives on biosimilars , 2019, Journal of Industrial Microbiology & Biotechnology.

[47]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[48]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[49]  P. Valensi,et al.  Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group , 2019, Cardiovascular Diabetology.

[50]  M. Pencina,et al.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial , 2019, JAMA.

[51]  G. Freckmann,et al.  Measures of Accuracy for Continuous Glucose Monitoring and Blood Glucose Monitoring Devices , 2018, Journal of diabetes science and technology.

[52]  K. Shipman,et al.  HbA1c: a review of non-glycaemic variables , 2018, Journal of Clinical Pathology.

[53]  R. Beck,et al.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.

[54]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[55]  Y. Bao,et al.  Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes , 2018, Diabetes Care.

[56]  FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes , 2018, Case Medical Research.

[57]  T. Einarson,et al.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.

[58]  P. Valensi,et al.  Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group , 2018, Cardiovascular Diabetology.

[59]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[60]  Publisher's Note , 2018, Anaesthesia.

[61]  K. Tuttle,et al.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[62]  Lara A Kahale,et al.  Living systematic reviews: 4. Living guideline recommendations. , 2017, Journal of clinical epidemiology.

[63]  G. Frühbeck,et al.  Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way , 2017, Obesity Facts.

[64]  Carol F. Kirchhoff,et al.  Biosimilars: Key regulatory considerations and similarity assessment tools , 2017, Biotechnology and bioengineering.

[65]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[66]  E. Akl,et al.  Living systematic review: 1. Introduction-the why, what, when, and how. , 2017, Journal of clinical epidemiology.

[67]  A. Vulto,et al.  The process defines the product: what really matters in biosimilar design and production? , 2017, Rheumatology.

[68]  Xifeng Wu,et al.  Diabetes with early kidney involvement may shorten life expectancy by 16 years. , 2017, Kidney international.

[69]  P. Valensi,et al.  Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group , 2017, Cardiovascular Diabetology.

[70]  Manu V. Venkat,et al.  More Than 7 Years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications , 2016, Clinical Diabetes.

[71]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[72]  G. Rayman.  Glycaemic control, glucose variability and the Triangle of Diabetes Care , 2016 .

[73]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[74]  P. Valensi,et al.  Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group , 2016, Cardiovascular Diabetology.

[75]  He Bai,et al.  Analytical Similarity Assessment in Biosimilar Studies , 2016, The AAPS Journal.

[76]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[77]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[78]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[79]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[80]  D. Nathan,et al.  Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) , 2013, Diabetes Care.

[81]  G. Laekeman.  Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues , 2013 .

[82]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[83]  S. Dagogo-Jack,et al.  Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection , 2011, Journal of clinical hypertension.

[84]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[85]  Z. Bloomgarden,et al.  Review of hemoglobin A1c in the management of diabetes , 2009, Journal of diabetes.

[86]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[87]  M. Kuhlmann,et al.  The protein science of biosimilars. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[88]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[89]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[90]  Anonymous.  Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline , 2022 .

[91]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[92]  J. Shaw,et al.  Epidemiology of polyneuropathy in diabetes and prediabetes. , 2014, Handbook of clinical neurology.

[93]  G. Moneta.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .

[94]  Michael E. Miller,et al.  ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .

[95]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[96]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[97]  No Authors.  Standards of Medical Care in Diabetes — 2021 , 2022, KIDNEYS.

[98]  Australian Evidence-Based Clinical Guidelines for Diabetes , 2022 .